Copyright
©2010 Baishideng Publishing Group Co.
World J Gastroenterol. Nov 14, 2010; 16(42): 5297-5305
Published online Nov 14, 2010. doi: 10.3748/wjg.v16.i42.5297
Published online Nov 14, 2010. doi: 10.3748/wjg.v16.i42.5297
Table 1 Clinical features of the studied groups n (%)
Variables | Treated group (n = 90) | Control group (n = 50) |
Age (yr, mean ± SD) | 50.27 ± 6.05 | 50.9 ± 7.23 |
Sex | ||
Male | 78 (86.7) | 39 (78) |
Female | 12 (13.3) | 11 (22) |
Residence | ||
Urban | 30 (33.33) | 20 (40) |
Rural | 60 (66.66) | 30 (60) |
Jaundice | 36 (40) | 21 (42) |
Encephalopathy | 21 (23.33) | 15 (30) |
Weight loss | 57 (63.33) | 29 (58) |
Ascites and lower limb edema | 78 (86.66) | 41 (82) |
Peripheral erythema | 75 (83.33) | 39 (78) |
Bleeding tendency | 48 (53.33) | 26 (52) |
Hematemesis | 24 (26.66) | 12 (24) |
Quantitative HCV RNA PCR (IU/mL) | 1 128 230-1 810 530 | 1 235 650-1 754 150 |
Table 2 Ultrasonographic features of the studied groups n (%)
Variables | Treated group (n = 90) | Control group (n = 50) |
Liver size | ||
Average | 27 (30) | 16 (32) |
Shrunken | 54 (60) | 23 (46) |
Enlarged | 9 (10) | 11 (22) |
Liver texture | ||
Cirrhotic | 90 (100) | 50 (100) |
Focal lesions | 0 | 0 |
Spleen | ||
Average sized | 24 (26.66) | 12 (24) |
Mild splenomegaly | 48 (53.33) | 29 (58) |
Moderate splenomegaly | 18 (20) | 9 (18) |
Huge splenomegaly | 0 | 0 |
Splenectomy | 0 | 0 |
Ascites | ||
Absent | 6 (6.7) | 8 (16) |
Mild | 12 (13.3) | 5 (10) |
Moderate | 63 (70) | 32 (64) |
Massive | 9 (10) | 5 (10) |
Table 3 Biochemical changes in the studied groups (mean ± SD)
Pre treatment | 1st month | 2nd month | 3rd month | 6th month | |
Bilirubin (mg%) | |||||
Patients | 2.51 ± 1.94 | 2.75 ± 1.66 | 2.31 ± 1.33 | 2.34 ± 1.29 | 2.18 ± 1.28 |
Control | 2.68 ± 1.49 | 2.80 ± 1.51 | 2.92 ± 1.71 | 3.41 ± 1.77 | 3.58 ± 1.56 |
P < 0.001 | P < 0.002 | P < 0.003 | |||
Albumin (gm/dL) | |||||
Patients | 2.61 ± 0.44 | 2.73 ± 0.62 | 2.83 ± 0.39 | 2.92 ± 0.33 | 2.94 ± 0.45 |
Control | 2.69 ± 0.26 | 2.60 ± 0.30 | 2.54 ± 0.25 | 2.44 ± 0.35 | 2.10 ± 0.34 |
P < 0.04 | P < 0.001 | ||||
PC (%) | |||||
Patients | 46.2 ± 12.5 | 49.6 ± 12.5 | 55.0 ± 14.5 | 54.9 ± 12.9 | 56.1 ± 15.7 |
Control | 45.1 ± 12.8 | 44.9 ± 13.1 | 42.2 ± 13.5 | 40.9 ± 14.1 | 35.8 ± 15.9 |
P < 0.005 | P < 0.005 | P < 0.005 | P < 0.005 | ||
AST (U/L) | |||||
Patients | 78.2 ± 32.1 | 67.4 ± 25.2 | 68.0 ± 20.2 | 61.0 ± 18.7 | 69.0 ± 29.2 |
Control | 75.4 ± 35.2 | 77.2 ± 30.1 | 72.1 ± 32.3 | 75.5 ± 33.3 | 80.2 ± 32.4 |
P < 0.002 | P < 0.002 | P < 0.003 | P < 0.003 | ||
ALT (U/L) | |||||
Patients | 51.5 ± 25.5 | 45.7 ± 19.6 | 50.9 ± 27.7 | 42.8 ± 16.1 | 47.0 ± 21.3 |
Control | 60.1 ± 20.4 | 62.5 ± 21.2 | 66.1 ± 25.1 | 63.5 ± 23.7 | 23.7 ± 22.1 |
P < 0.001 | P < 0.001 | P < 0.01 | P < 0.01 |
Table 4 Response rate of the treated group according to synthetic and biochemical liver functions n (%)
Marker | Responders | Stable | Non-responders | P value | |||||||||
1st mo | 2nd mo | 3rd mo | 6th mo | 1st mo | 2nd mo | 3rd mo | 6th mo | 1st mo | 2nd mo | 3rd mo | 6th mo | ||
Bilirubin | 24 (26.6) | 30 (37.0) | 33 (46.5) | 39 (56.5) | 0 (0) | 9 (11.1) | 9 (12.8 ) | 0 (0) | 66 (73.3) | 42 (51.9) | 29 (40.8) | 30 (43.5) | 0.516 |
Albumin | 57 (63.3) | 45 (55.6) | 42 (59.2) | 40 (58.0) | 3 (3.33) | 9 (11.1) | 9 (12.7) | 8 (11.6) | 30 (33.3) | 27 (33.3) | 20 (28.1) | 21 (30.4) | 0.069 |
PC | 66 (73.3) | 57 (70.4) | 47 (66.2) | 48 (65.6) | 0 (0) | 3 (3.6) | 6 (8.5) | 0 (0) | 24 (26.6) | 21 (25.8) | 18 (25.4) | 21 (30.4) | 0.023 |
AST | 57 (63.3) | 48 (60.3) | 47 (66.2) | 39 (56.5) | 3 (3.33) | 0 (0) | 0 (0) | 0 (0) | 30 (33.3) | 33 (40.7) | 24 (33.8 ) | 30 (43.5) | 0.673 |
ALT | 54 (60.0) | 48 (59.2) | 47 (66.2) | 30 (43.5) | 0 (0) | 3 (3.7) | 6 (8.5) | 6 (8.7) | 36 (40.0) | 30 (37.1) | 18 (25.3) | 33 (47.8) | 0.550 |
Table 5 Cross-table showing progress of hepatic coma and hematemesis after 1, 2, 3 and 6 mo n (%)
Pretreatment (n = 90) | 1 mo (n = 90) | 2 mo (n = 81) | 3 mo (n = 71) | 6 mo (n = 69) | ||||||
No | Yes | No | Yes | No | Yes | No | Yes | No | Yes | |
Coma | ||||||||||
Studied group | 60 (66.7) | 30 (33.3) | 87 (96.7) | 3 (3.3) | 72 (89) | 9 (11) | 66 (92.9) | 5 (7.1) | 63 (91.3) | 6 (8.7) |
50 patients | 50 patients | 44 patients | 34 patients | 26 patients | ||||||
Control group | 31 (62) | 19 (38) | 29 (48) | 21 (42) | 24 (54.5) | 20 (45.5) | 14 (41.2) | 20 (58.8) | 5 (19.2) | 21 (80.7) |
Hematemesis | ||||||||||
Studied group | 72 (80) | 18 (20) | 90 (100) | 0 (0) | 75 (92.6) | 6 (7.4) | 68 (95.8) | 3 (4.2) | 60 (87) | 9 (13) |
50 patients | 50 patients | 44 patients | 34 patients | 26 patients | ||||||
Control group | 35 (70) | 15 (30) | 32 (64) | 18 (36) | 24 (54.5) | 20 (54.5) | 12 (35.3) | 24 (70.6) | 6 (23) | 20 (77) |
Table 6 Response rate of the treated group in relation to clinical features n (%)
Marker | Responders | Stable | Non-responders | P value | |||||||||
1st mo | 2nd mo | 3rd mo | 6th mo | 1st mo | 2nd mo | 3rd mo | 6th mo | 1st mo | 2nd mo | 3rd mo | 6th mo | ||
Child-Pugh score | 9 (10) | 18 (22.2) | 21 (29.6) | 27 (39.1) | 72 (80) | 48 (59.3) | 45 (63.4) | 39 (56.2) | 3 (10) | 15 (18.5) | 5 (7.0) | 3 (4.4) | 0.03 |
Performance score | 18 (20) | 27 (33.3) | 42 (59.2) | 42 (60.9) | 51 (56) | 36 (44.4) | 18 (25.4) | 18 (26.1) | 21 (23.2) | 18 (22.2) | 11 (15.4) | 9 (13) | 0.02 |
Degree of ascites | 33 (36) | 42 (51.8) | 44 (62.0) | 45 (65.2) | 48 (53) | 24 (29.6) | 21 (29.5) | 24 (34.8) | 9 (10) | 15 (18.6) | 6 (8.5) | 0 (0) | 0.02 |
Hepatitis C coma | 27 (30) | 24 (29.7) | 24 (33.8) | 24 (34.9) | 63 (70) | 54 (66.6) | 47 (66.2) | 42 (60.8) | 0 (0) | 3 (3.7) | 0 (0) | 3 (4.3) | 0.001 |
Haematemesis | 18 (20) | 21 (25.9) | 21 (29.6) | 18 (26.1) | 72 (80) | 57 (70.4) | 50 (70.4) | 48 (69.6) | 0 (0) | 3 (3.7) | 0 (0) | 3 (4.3) | 0.03 |
Table 7 Multivariate analysis of hepatitis C virus viral titer vs clinical features of the responding group
Beta | T | P value | |
Child-Pugh score | 27.44 | 1.65 | 0.03 |
Performance score | 41.2 | 2.6 | 0.02 |
Degree of ascites | 35.03 | 1.3 | 0.02 |
Hepatic coma | 29.1 | 1.2 | 0.001 |
Haematemesis | 26.8 | 1.4 | 0.03 |
- Citation: Salama H, Zekri ARN, Bahnassy AA, Medhat E, Halim HA, Ahmed OS, Mohamed G, Alim SAA, Sherif GM. Autologous CD34+ and CD133+ stem cells transplantation in patients with end stage liver disease. World J Gastroenterol 2010; 16(42): 5297-5305
- URL: https://www.wjgnet.com/1007-9327/full/v16/i42/5297.htm
- DOI: https://dx.doi.org/10.3748/wjg.v16.i42.5297